1. "Early Drug Development Service"
  2. "Oxford University Press"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (11)
  3. Editorial (2)
Groups
  1. Department of Medicine (39)
  2. Early Drug Development Service (39)
  3. Solid Tumor Oncology Division (39)
  4. Thoracic Oncology (16)
  5. Gynecologic Medicine Service (14)
  6. GSK Faculty (12)

More Groups

People
  1. David Hyman (26)
  2. Alexander Drilon (16)
  3. Alison Schram (12)
  4. Ezra Rosen (7)
  5. David Solit (4)
  6. Marc Ladanyi (4)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (5)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (14)

More Years

Publications
  1. Annals of Oncology (33)
  2. Neuro-Oncology (3)
  3. JNCI: Journal of the National Cancer Institute (1)
  4. Journal of the American Medical Informatics Association (1)
  5. The Oncologist (1)
Publishers
  1. Oxford University Press (39)

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors
    Journal Article

    Garralda, E.; Schram, A. M.; Bedard, P. L.; Schwartz, G. K.; Yuen, E.; McNeely, S. C.; Ribeiro, S.; Cunningham, J.; Wang, Y.; Urunuela, A.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
    Meeting Abstract

    Heredia, J. B.; Diplas, B. H.; El Nahhas, O. S. M.; Selenica, P.; Pareja, F.; Mandelker, D.; Weigelt, B.; Riaz, N.; Rosen, E.; Sfeir, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • EZH2 inhibition: It's all about the context
    Editorial

    Rosen, E. Y.; Shukla, N. N.; Glade Bender, J. L.
    JNCI: Journal of the National Cancer Institute (2023)

    Fulltext@MSK | Save
  • Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
    Meeting Abstract

    Park, J. O.; Meng, D. T. W.; Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Cassier, P.; Kamath, S. D.; Dotan, E.; Kim, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
    Meeting Abstract

    Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
    Meeting Abstract

    Lheureux, S.; Rosen, E.; Lee, E.; Spigel, D.; Højgaard, M.; Fontana, E.; Mettu, N. B.; Carter, L.; Patel, S.; Papp, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase
    Meeting Abstract

    Lee, E.; Yap, T. A.; Fontana, E.; Rosen, E.; Spigel, D.; Lheureux, S.; Mettu, N. B.; Carter, L.; Plummer, R.; Patel, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save